Project Management Standards Applied to Complex Clinical Trials. Disclaimer
|
|
- Jodie McCoy
- 6 years ago
- Views:
Transcription
1 Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2
2 Topics Typical Issues in Clinical Trials Project Management Standards Some Project Management Standards Key Knowledge Areas PM Standards and Clinical Trials Summary 3 Typical Issues with Clinical Trials Duration and Cost exceeded Too many uncertainties (assumptions) No effective cost control No effective schedule control Reactive Risk Management Risks are addressed too late Risk prevention is not a team effort No budget for contingencies 4
3 Typical Issues with Clinical Trials Quality Issues Quality issues detected late, e.g. systematic protocol violations prior to DB lock, or data issues detected once statistical analysis was completed Communication and Team Issues Rare and ineffective meetings No ongoing training 5 Typical Issues with Clinical Trials Frequent Scope Changes Stakeholders requests Regulatory requirements Marketing requirements Misunderstandings between sponsor and service providers regarding activities contained in agreed upon working packages / tasks 6
4 Project Management Standards PMBOK Project Management Body of Knowledge ICB International Competence Baseline PRINCE2 Projects In Controlled Environments Several national and industry specific standards 7 Project Management Standards Key PM Knowledge Areas: Scope Time Budget Human Resources Quality Communication and Stakeholders Risk Procurement Project Integration Integration of all areas Change control 8
5 PM Standards and Clinical Trials The well known PM standards (PMBOK, ICB, PRINCE2, etc.) are not industry specific Clinical trials are fully featured projects, having all characteristics of a typical project. 9 PM Standards and Clinical Trials Are the typical issues of clinical trials addressed by the key PM knowledge areas? Duration and Cost exceeded Reactive Risk Management Quality Issues Communication and Team Issues Frequent Scope Changes 10
6 Key Principles from PM Standard All Projects Are Unique There s no standard project plan which will perfectly fit. But it is useful to use plans of similar projects as templates. Project management team is responsible for defining project specific procedures, processes, planning detail and strategies, in the context of the performing organization. 11 Key Principles from PM Standard Monitoring & Controlling Processes Planning Processes Initiating Processes Closing Processes Executing Processes The Deming Wheel (Plan-Do-Check-Act Cycle) 12
7 Key Principles of PM Standards Planning is key for a successful execution of the project as well as for successful change control Planning how to plan is key for a good project plan! 21 out of 44 PMBOK processes are about planning 13 Summary Clinical Trials are projects and should be managed as such The most known project management standards are not industry specific. They can be applied to clinical projects and will address all of the recurring issues Good project planning is the key for success! 14
8 Any Questions? 15 Thank You Very Much! 16
High Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationConstructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer
Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationQPPV Association and Training Part 2 Session Introduction
QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationPromotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company
Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the
More informationSPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs
SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides
More informationDo Niche CROs have a Role in Drug Development?
Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationUtilities and Pitfalls of Modeling & Simulation in Pivotal Trials
Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials H.M. James Hung, Ph.D Div. of Biometrics I, OB/OTS/CDER U.S. Food and Drug Administration Presented in PhRMA/FDA Workshop, October 28,
More informationUpdate on New MedDRA SOC Product issues
Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationGeneral Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria
EDC-System Selection From the point of view of small to mid-size CROs Steffen König General Manager IST GmbH - Mannheim 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationInto the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith
Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in
More informationAndrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer
Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The
More informationLabelling Harmonization 2011
Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationesource What EDC Should Be Presenter: Ed Seguine President
esource What EDC Should Be Presenter: Ed Seguine President The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationProject Management Competencies. Disclaimer 28/06/2011
Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions
More informationEffective Project Leadership and Management: Disclaimer
Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More informationUsing etechnologies to Increase Efficiency and Quality in Regulatory Operations
Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following
More informationDelivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens
Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationQbD Approach and Regulatory Challenges in Japan
QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationEffective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
More informationPharmacovigilance in Asia: The China Perspectives. Disclaimer
Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in
More informationSharing Regulatory Intelligence: Best Practices and Case Studies
Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationPMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationEugène van Puijenbroek, MD, PhD
Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed
More informationPM tutor. The Business Case, SOW and The Project Charter. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence
PM tutor Empowering Excellence The Business Case, SOW and The Project Charter Presented by Dipo Tepede, PMP, SSBB, MBA This presentation is copyright 2009 by POeT Solvers Limited. All rights reserved.
More informationPanama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)
DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance
More informationPROJECT MANAGEMENT PLAN INTRODUCTION. 1 Powered by POeT Solvers Limited
PROJECT MANAGEMENT PLAN INTRODUCTION 1 www.pmtutor.org Powered by POeT Solvers Limited This presentation is copyright 2013 by POeT Solvers Limited. All rights reserved. This presentation is protected by
More informationDevelopment of Orphan Drugs Regulatory Viewpoints from PMDA
Development of Orphan Drugs Regulatory Viewpoints from PMDA Ken Sakushima Office of Cellular and Tissue-based Products, Office of New Drug III Pharmaceuticals and Medical Devices Agency (PMDA) Disclaimer
More informationHow to successfully Implement and Leverage the Regulatory Intelligence Function
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationHow can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise
How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation
More informationectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA
ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationModeling and Simulation for Dose Selection using Adaptive Designs
Modeling and Simulation for Dose Selection using Adaptive Designs Nitin Patel Chairman and C.T.O. Cytel, Inc. Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationData standardization and advancing regulatory science
Data standardization and advancing regulatory science Yoshiaki Uyama, Ph.D. Pharmaceuticals & Medical Devices Agency (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor,
More informationStructured Content Management [SCM]
Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint
More informationProcedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011
Harmonization of Labeling Across Products with Same Active Moiety in the EU Procedures in Regard to Entire Product Information Texts Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Disclaimer The
More informationTransforming Regulatory Affairs through Technology - End to End Tech Platform Approach
Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Peter Lassoff, PharmD, FTOPRA VP & Head, Global Regulatory Affairs IQVIA Disclaimer The views and opinions expressed
More informationThe views and opinions expressed in the following PowerPoint slides are
Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views
More informationPMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA
PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed
More informationProject Management Training Brochure
Project Management Training Brochure We develop project management training sessions by integrating our 40 years of combined practitioner experience with the most current project management knowledgebase
More informationLabelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines
Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe
More informationHuman Vss Prediction. James Yates AstraZeneca. Disclaimer 10/25/2011
0/25/20 Human Vss Prediction Part 2: Comparative Assessment of Prediction Methods of Human Volume of Distribution R.D.O JONES,H.M. JONES, M. ROWLAND, C.R. GIBSON, J.W.T. YATES, J.Y. CHIEN, B. J. RING,
More informationDrug development and evaluation with small clinical Trials from the regulatory point of view
Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency
More informationStakeholder education on biosimilar concepts - why does it matter globally?
Stakeholder education on biosimilar concepts - why does it matter globally? Dr Virginia Acha Director, Regulatory Policy Europe, Middle East and Africa Amgen 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationPMBOK Guide Sixth Edition Updates and Agile Alignment By Tony Johnson July 2017
PMBOK Guide Sixth Edition Updates and Agile Alignment By Tony Johnson July 2017 Trademarks and Copyrights Materials in this presentation are based on the text, A Guide to the Project Management Body of
More informationRegulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation
Regulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation Dr Yoshiaki Uyama Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions
More informationImplementation of EU Falsified Medicines Directive
Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationCMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10
CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationNAS and KAS Industry perspective
NAS and KAS Industry perspective Henk Schuring Group Vice President Regulatory Affairs Europe Genzyme Europe BV, Netherlands 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationOverview of A Guide to the Project Management Body of Knowledge (PMBOK Guide) Fourth Edition Changes
Overview of A Guide to the Project Management Body of Knowledge (PMBOK Guide) Fourth Edition Changes PMI -- Project Management Institute» Leading global association for the project management profession»
More informationProject Management Body of Knowledge (PMBoK)
Project Management Body of Knowledge (PMBoK) Knowledge & Practice Areas Project Management PMBoK Prince 2 ISO 10006 General Management Application high performance sport 2 Theory vs. Practice: A Disclaimer
More informationGuten Tag. (good day)
Guten Tag (good day) 4.5 Perform Integrated Change Control How a person may percieve change: paideiagroup.com 4.5 Perform Integrated Change Control Consider what change is: Crossing unknown territory Departing
More informationTrial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1
Trial Master File Reference Model Project Charter Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Prepared by The Exchange Mechanism Standard Subgroup of the TMF Reference
More informationHow to Implement a Successful e-archiving Function Within a Multinational Company
How to Implement a Successful e-archiving Function Within a Multinational Company Huguette BESSARD Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationInterdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines
Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Richard Dolinar, MD Chairman, Alliance for Safe Biologic Medicines Disclaimer The views and opinions expressed
More informationProject Management for Non-Profits What s in it for you? Benefits of Improved Project Management (PM) Skills, Techniques and Processes.
Project Management for Non-Profits What s in it for you? Benefits of Improved Project Management (PM) Skills, Techniques and Processes Nov 2014 1 Overview What is a project? Impact on organizational results
More informationProject Management Process Groups. PMP Study Group Based on the PMBOK Guide 4 th Edition
Project Management Process Groups PMP Study Group Based on the PMBOK Guide 4 th Edition Introduction PM Process Groups In order for a project to be successful, the project team must: Select appropriate
More informationRegulatory Perspectives on NGS-based CDx
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake Regulatory Perspectives on NGS-based CDx Reiko Yanagihara, Ph.D. Office of In Vitro Diagnostics Deputy Review Director Pharmaceuticals
More informationINTEGRATION of PROJECT MANAGEMENT and SYSTEMS ENGINEERING
Copyright 2018 by Yves Theriault. Permission granted to INCOSE to publish and use. INTEGRATION of PROJECT MANAGEMENT and SYSTEMS ENGINEERING San Diego INCOSE Mini-Conference December 1, 2018 John Wood,
More informationProject Management Session 6.2. Project Initiation Phase Integration Management
Project Management Session 6.2 Project Initiation Phase Integration Management 1 Project Phases & Knowledge Areas 1. Integration 2. Scope Management 3. Time Management 4. Cost Management 5. Quality Management
More informationFalcon Training PMP & CAPM Exam Preparation Course
Falcon Training PMP & CAPM Exam Preparation Course Chapter 1-3: Project Framework Review Questions 1. What is the primary role of the portfolio manager? A. To deliver the unique product, service, or result
More informationDoes This Come With Instructions?
Does This Come With Instructions? Creating A Manual for Your Organization s Project Culture Russell Rivenbark M.P.M. RCDD, PMP New Hanover County Schools First, have a definite, clear practical ideal;
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationPRINCE2 VS PMBOK FRIEND OR FOE WOULDN T IT BE NICE:
PRINCE2 VS PMBOK FRIEND OR FOE A presentation to: PMI Vancouver Island Chapter May 21, 2009 Presented by: Julie Grabb PMP Prince2 Practitioner Prince2 Authorized Trainer WOULDN T IT BE NICE: Let the Project
More informationMentored Course Plan PMP (2013 version)
Module 1 Key Concepts Course overview What is a project? What is Project Management? The performing organisation o Project Management Office (PMO) Structure of the PMBOK o PM processes and process groups
More informationIntensive Course Plan CAPM 5 (2013 version)
Module 1 Key Concepts Course overview What is a project? What is Project? Project Office (PMO) Structure of the PMBOK o PM processes and process groups o IPECC o Process Interactions o Process Mapping
More informationPROGRAM MANAGEMENT PLANS AT TXDOT
PROGRAM MANAGEMENT PLANS AT TXDOT Transportation Programs Division PPM Fort Worth District Bryan District 6/6/18 Outline 1 Introduction to management plans 3-4 2 FHWA project management plans 5-7 3 4 5
More informationPM tutor. Manage Project Team Part 1. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence. Powered by POeT Solvers Limited
PM tutor Empowering Excellence Manage Project Team Part 1 Presented by Dipo Tepede, PMP, SSBB, MBA This presentation is copyright 2009 by POeT Solvers Limited. All rights reserved. This presentation is
More informationThe Practice of Integrated Change Control in Engineering Projects. Rakesh Patel, P.E., PMP
The Practice of Integrated Change Control in Engineering Projects Rakesh Patel, P.E., PMP Show of Hands Who all Manages Projects? What is Change Management? Change management is proactive management of
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationProject Management Body of Knowledge Chapter 3 Project Processes
Project Management Body of Knowledge Chapter 3 Project Processes PMP Exam Prep PMBOK Chapter 1 - Introduction Chapter 2 - Organizational Influences & Life Cycles Chapter 3 - Project Processes Chapter 3
More informationASA380 ASAP Methodology for Implementation in Details
ASAP Methodology for Implementation in Details SAP Solution Manager Course Version: 95 Course Duration: 3 Day(s) Publication Date: 01-03-2013 Publication Time: 1007 Copyright Copyright SAP AG. All rights
More informationProject Management in Clinical Trials. Presented by: Melanie Gentgall and Tim Dyke
Project Management in Clinical Trials Presented by: Melanie Gentgall and Tim Dyke We acknowledge the traditional custodians of the land on which we meet today, and pay respect to their elders past, present
More informationProject Management Framework with reference to PMBOK (PMI) July 01, 2009
Project Management Framework with reference to PMBOK (PMI) July 01, 2009 Introduction Context Agenda Introduction to Methodologies What is a Methodology? Benefits of an Effective Methodology Methodology
More information9th Annual SAS Health Care & Life Sciences Executive Conference
: An Integrated Platform to Promote Data Exchange, Collaboration, and Advanced Analytics 9th Annual SAS Health Care & Life Sciences Executive Conference 9-10 May 2012 Bernd Doetzkies, Director Informatics
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationRisk-Based Monitoring - Prospective from CRO
Risk-Based Monitoring - Prospective from CRO New Trends in Clinical Trials Taipei 2016 Tong Guo, PhD Head of Biostatistics, Africa & Asia QuintilesIMS Copyright 2015 Quintiles Disclaimer The views and
More informationRegulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer
Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following
More informationIII PMF MANAGEMENT SOLUTIONS. Course Number Project Management Course Overview
III PMF MANAGEMENT SOLUTIONS Course Number Project Management Course Overview House Keeping Beep beep (prepare to evacuate): Whoop whoop (evacuate): Follow the red hat (fire warden). Designated evacuation
More informationImpact of MRCT after ICH E17 fully implement -Industry perspective-
Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation
More informationRevision of the Variations Regulation. Key Principles and Guidelines Development CONTENT
DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types
More informationProject Management CSC 310 Spring 2018 Howard Rosenthal
Project Management CSC 310 Spring 2018 Howard Rosenthal 1 Notice This course is based on and includes material from the text: A User s Manual To the PMBOK Guide Authors: Cynthia Stackpole Snyder Publisher:
More informationAgile Program Management in Action
Agile Program Management in Action Agile Program Management in Action PRESENTATION CUTOUT PEOPLE SAMPLER Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the
More informationThe Planning Process Group
Assalam-o-alaikum Project Management Process Groups Project Integration Management Knowledge Areas Initiating Planning Executing Scope Time Cost Quality Human Resources Communications Monitoring & Controlling
More informationPMP PMBOK 5 th Edition Course Agenda
PMP PMBOK 5 th Edition Course Agenda 1. Introduction to PMP Course Certification What are PMI and PMP Application Requirements for the PMP Exam Guidelines to Fill Up the PMP Application About the PMP Exam
More informationPRINCE2 and the National and International Standards
PRINCE2 and the National and International Standards Robert Buttrick, Project Workout Limited White Paper December 2012 2 PRINCE2 and the National and International Standards Contents 1 Introduction 3
More informationAn Oracle White Paper October Why Projects Fail: Avoiding the Classic Pitfalls
An Oracle White Paper October 2010 Why Projects Fail: Avoiding the Classic Pitfalls Executive Summary There is an age-old saying that goes something like this: we can do anything we want, but we cannot
More informationSimilarity Assessment of Biosimilars. The Past, Present and Future State. Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016
Similarity Assessment of Biosimilars. The Past, Present and Future State Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016 Disclaimer The views and opinions expressed in the following PowerPoint
More informationProject Integration Management
Project Integration Management Presented by Project Masters Inc. *Throughout this presentation, we reference and recognize the following trademarks, service marks, and copyrights of the Project Management
More informationPMP in the Real World. Scott Bailey, MBA, PMP, SSGB
PMP in the Real World Scott Bailey, MBA, PMP, SSGB PMP in the Real World Webinar purpose To understand the relevance of the PMI PMP certification and its influence on the success or failure of projects
More informationProject Management Framework
Project Management Framework Study Notes PMI, PMP, CAPM, PMBOK, PM Network and the PMI Registered Education Provider logo are registered marks of the Project Management Institute, Inc. Points to Note Please
More informationProject Management Professional (PMP) Exam Prep Course 00 PMP Application & Exam
Project Management Professional (PMP) Exam Prep Course 00 PMP Application & Exam Slide 1 Application & Exam Types of Questions PM Basics Ten Knowledge Areas Professional Responsibility Practice Exams Slide
More information